论文部分内容阅读
目的探讨DNA倍体分析系统宫颈癌筛查的应用价值。方法对324例宫颈上皮细胞DNA倍体分析异常的妇女,在阴道镜下多点宫颈活体组织病理检查的临床资料进行分析。结果 DNA倍体异常的324例中,病理诊断为宫颈上皮内瘤变(CIN)或宫颈癌99例,占37.79%。在62例阴道镜图像正常者中,仍发现4例为CIN,有6.45%的漏诊率。结论 DNA倍体分析系统作为早期宫颈癌筛查的一种新方法,与阴道镜联合应用可提高诊断CIN和早期宫颈癌的敏感性。
Objective To explore the value of DNA ploidy analysis system for cervical cancer screening. Methods 324 cases of cervical epithelial cell DNA ploidy analysis of abnormal women in colposcopic multi-point cervical biopsy clinical data analysis. Results In 324 cases of DNA ploidy abnormalities, pathological diagnosis of cervical intraepithelial neoplasia (CIN) or 99 cases of cervical cancer, accounting for 37.79%. Among the 62 cases with normal colposcopy images, 4 cases were still found to have CIN with a missed diagnosis rate of 6.45%. Conclusion DNA ploidy analysis system as a new screening method for early cervical cancer, combined with colposcopy can improve the sensitivity of diagnosis of CIN and early cervical cancer.